zuranolone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| steroids not used as glucocorticosteroids | 5738 | 1632051-40-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The mechanism of action of zuranolone in the treatment of PPD is not fully understood, but is thought to be related to its positive allosteric modulation of GABAA receptors.
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 4, 2023 | FDA | SAGE THERAP |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
None
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Postpartum depression | indication | 58703003 | DOID:9478 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| GABA-A receptor alpha-1/beta-2/gamma-2 | Ion channel | ALLOSTERIC MODULATOR | EC50 | 6.37 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE | |||
| GABA A receptor alpha-4/beta-3/delta | Ion channel | ALLOSTERIC MODULATOR | EC50 | 6.93 | SCIENTIFIC LITERATURE | SCIENTIFIC LITERATURE |
External reference:
| ID | Source |
|---|---|
| CHEMBL4105630 | ChEMBL_ID |
| C000634505 | MESH_SUPPLEMENTAL_RECORD_UI |
| 12858 | IUPHAR_LIGAND_ID |
| DB15490 | DRUGBANK_ID |
| C5227595 | UMLSCUI |
| 10896 | INN_ID |
| 86294073 | PUBCHEM_CID |
| D11793 | KEGG_DRUG |
| 7ZW49N180B | UNII |
Pharmaceutical products:
None